Amneal Pharmaceuticals Inc's fundamentals are relatively stable, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amneal Pharmaceuticals Inc's Score
Industry at a Glance
Industry Ranking
26 / 159
Overall Ranking
94 / 4563
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Amneal Pharmaceuticals Inc Highlights
StrengthsRisks
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.29% year-on-year.
Overvalued
The company’s latest PE is 727.83, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 154.45M shares, decreasing 11.78% quarter-over-quarter.
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Ticker SymbolAMRX
CompanyAmneal Pharmaceuticals Inc
CEOPatel (Chintu)
Websitehttps://amneal.com/
FAQs
What is the current price of Amneal Pharmaceuticals Inc (AMRX)?
The current price of Amneal Pharmaceuticals Inc (AMRX) is 13.250.
What is the symbol of Amneal Pharmaceuticals Inc?
The ticker symbol of Amneal Pharmaceuticals Inc is AMRX.
What is the 52-week high of Amneal Pharmaceuticals Inc?
The 52-week high of Amneal Pharmaceuticals Inc is 13.485.
What is the 52-week low of Amneal Pharmaceuticals Inc?
The 52-week low of Amneal Pharmaceuticals Inc is 6.685.
What is the market capitalization of Amneal Pharmaceuticals Inc?
The market capitalization of Amneal Pharmaceuticals Inc is 4.16B.
What is the net income of Amneal Pharmaceuticals Inc?
The net income of Amneal Pharmaceuticals Inc is -116.89M.
Is Amneal Pharmaceuticals Inc (AMRX) currently rated as Buy, Hold, or Sell?
According to analysts, Amneal Pharmaceuticals Inc (AMRX) has an overall rating of Buy, with a price target of 14.500.
What is the Earnings Per Share (EPS TTM) of Amneal Pharmaceuticals Inc (AMRX)?
The Earnings Per Share (EPS TTM) of Amneal Pharmaceuticals Inc (AMRX) is 0.018.